Ultragenyx Completes Rolling BLA for DTX401, AAV Gene Therapy for Glycogen Storage Disease

Ultragenyx submits its BLA for DTX401, an AAV8-delivered gene therapy expressing the human G6PC gene for glycogen storage disease type Ia. The submission marks another rare disease gene therapy approaching the FDA finish line in a crowded 2026 regulatory calendar.